The FDA has approved Litfulo, a once-daily oral treatment, for the treatment of severe alopecia in individuals aged 12 years and older, Pfizer announced in a press release. Litfulo (ritlecitinib), a selective dual Janus kinase 3 and tyrosine family kinase inhibitor, is now the first-ever FDA-approved treatment for severe alopecia in adolescents, according to the press release.
PureTech Announces Annual Results for Year Ended December 31, 2020
By
Staff
2 seconds ago
Strong capital base and cash runway extended into the first quarter of 2025, with PureTech level cash and cash equivalents of $443.4 million as of March 31, 2021
1 ($349.4 million as of December 31, 2020
2) and consolidated cash and cash equivalents of $486.5 million as of March 31, 2021
3 ($403.9 million as of December 31, 2020
4)
Advancement of Wholly Owned Pipeline with four clinical trial initiations and one successful readout, with three clinical trials ongoing
Significant milestones across PureTech’s Founded Entities including one FDA Clearance for Marketing, two European Marketing Authorizations, initiation of a Phase 3 program, $247.8 million raised in 2020
5 and $473.2 million raised in the 2021 post-period
An MGH pilot study evaluating scalp skin disruption using Follica’s proprietary Hair Follicle Neogenesis stimulation product was published in International Journal of Women’s Dermatology, demonstrating the treatment promoted hair growth in female pattern hair loss. The study endpoints included photographs, patient-reported improvement and physician-documented Sinclair score.
The pilot study, led by Maryanne M. Senna, M.D., an assistant professor of dermatology at Harvard Medical School, enrolled 11 women with mild to moderate FPHL who had been on stable existing treatments for six or more months. Patients underwent six treatments with the Follica proprietary Hair Follicle Neogenesis (HFN) device and application of a topical on-market drug on non-treatment days. The scalp treatments with the HFN device, which last just a few minutes, stimulate stem cells and enable the growth of new hair follicles. A topical drug is then applied to enhance efficacy by thickening new hair follicle
An MGH pilot study evaluating scalp skin disruption using Follica’s proprietary Hair Follicle Neogenesis stimulation product was published in International Journal of Women’s Dermatology, demonstrating the treatment promoted hair growth in female pattern hair loss. The study endpoints included photographs, patient-reported improvement and physician-documented Sinclair score.
The pilot study, led by Maryanne M. Senna, M.D., an assistant professor of dermatology at Harvard Medical School, enrolled 11 women with mild to moderate FPHL who had been on stable existing treatments for six or more months. Patients underwent six treatments with the Follica proprietary Hair Follicle Neogenesis (HFN) device and application of a topical on-market drug on non-treatment days. The scalp treatments with the HFN device, which last just a few minutes, stimulate stem cells and enable the growth of new hair follicles. A topical drug is then applied to enhance efficacy by thickening new hair follicle